Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine or alfentanil combined with propofol for painless colorectal endoscopy
ChiCTR2200062605Phase 4Recruiting
- Sponsor
- Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
- Start
- Jun 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine, alfentanil, sufentanil and propofol in gastrointestinal conditions (3 arms), sponsored by Central Hospital of Enshi Tujia and Miao Autonomous Prefecture. Primary endpoints: respiratory depression, hypotension and 12 more. Started Jun 2022; status: recruiting.
02
Drugs
esketaminealfentanilsufentanilpropofol
03
Conditions
gastrointestinal conditions
Beyond the preview
Go deeper on ChiCTR2200062605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062605.